XM does not provide services to residents of the United States of America.

Activist investor Cevian ups stake in Baloise to 9.4%



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 1-Activist investor Cevian ups stake in Baloise to 9.4%</title></head><body>

Adds comment from Baloise, further details

ZURICH, Sept 9 (Reuters) -Activist investor Cevian Capital has increased its stake in Baloise Holding BALN.S, it said on Monday, increasing its ability to force changes at the Swiss insurer.

Cevian now holds around 9.4% in Baloise, the biggest investor in the company.

The investment is an increase from the 3.12% stake held by Cevian in Baloise revealed earlier this year. According to Swiss stock market disclosures, the stake was increased to 5.11% by June.

"Baloise has the opportunity to become a top-performing Swiss insurer," said Robert Schuchna, a partner at Cevian. "We believe there is significant value potential in the company."

Cevian, which has offices in Stockholm, London and near Zurich, previously invested in Swiss engineering group ABB ABBN.S and last year reported a position in UBS UBSG.S, saying it wanted to double the value of its stake.

It has so far not revealed its plans for Baloise.

The investor is pressing for a strategic overhaul of the company, said The Financial Times, which first reported the increased stake.

Cevian wants Baloise's management to refocus the group on countries where it is strongest and has a high market share, and direct more of its cash generation to shareholder returns and investing in its domestic market, the newspaper said, citing people familiar with its thinking.

The increased stake comes after Baloise shareholders voted in April to scrap a 2% cap on voting rights, which had previously limited their influence on the company's management.

Baloise has endured a tough few years, with the Basel company's share price trailing rival insurers while investors have raised concerns the performance of its businesses outside its Swiss home market.

Over the last two years, the company's stock has struggled, underperforming its insurance peers .SXIP by nearly 15%.

"We are looking forward to September 12, when we will explain Baloise's strategic direction at our investor update," a Baloise spokesman said.

The company is due to publish its half-year results and give an investor update on that day, where it is expected to unveil new mid-term targets.



Reporting by Oliver Hirt and John Revill, additional reporting by Gnaneshwar Rajan in Bengaluru;; editing by Diane Craft and Kim Coghill

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.